|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
389,580,000 |
Market
Cap: |
50.01(B) |
Last
Volume: |
1,778,975 |
Avg
Vol: |
1,913,734 |
52
Week Range: |
$75.49 - $140.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 487 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
214,480 |
283,298 |
303,316 |
571,262 |
Total Sell Value |
$28,881,982 |
$37,155,070 |
$39,545,240 |
$69,827,197 |
Total People Sold |
7 |
12 |
14 |
16 |
Total Sell Transactions |
14 |
29 |
47 |
80 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Dahut Karen M |
Director |
|
2022-05-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(918) |
773 |
|
- |
|
Topol Eric |
Director |
|
2022-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
919 |
92,766 |
|
- |
|
Topol Eric |
Director |
|
2022-05-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(919) |
0 |
|
- |
|
Augustinos Nicholas |
Director |
|
2022-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
918 |
8,510 |
|
- |
|
Augustinos Nicholas |
Director |
|
2022-05-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(918) |
0 |
|
- |
|
Altman Steven R |
Director |
|
2022-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
910 |
14,696 |
|
- |
|
Altman Steven R |
Director |
|
2022-05-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(910) |
0 |
|
- |
|
Kahn Barbara |
Director |
|
2022-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
918 |
3,918 |
|
- |
|
Kahn Barbara |
Director |
|
2022-05-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(918) |
0 |
|
- |
|
Collins Richard Alexander |
Director |
|
2022-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
910 |
8,114 |
|
- |
|
Collins Richard Alexander |
Director |
|
2022-05-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(910) |
0 |
|
- |
|
Patterson Chad |
EVP Global Marketing |
|
2022-05-09 |
4 |
AS |
$342.77 |
$266,332 |
D/D |
(777) |
13,675 |
|
-73% |
|
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2022-04-25 |
4 |
AS |
$439.94 |
$109,985 |
D/D |
(250) |
35,425 |
|
-81% |
|
Patterson Chad |
EVP, Global Marketing |
|
2022-04-11 |
4 |
AS |
$498.75 |
$387,030 |
D/D |
(776) |
14,452 |
|
-83% |
|
Regan Barry J. |
EVP Global Operations |
|
2022-03-29 |
4 |
AS |
$500.00 |
$553,000 |
D/D |
(1,106) |
16,345 |
|
-82% |
|
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2022-03-23 |
4 |
AS |
$459.98 |
$114,995 |
D/D |
(250) |
35,675 |
|
-80% |
|
Dolan Matthew Vincent |
SVP Corporate Development |
|
2022-03-17 |
4 |
AS |
$450.00 |
$217,800 |
D/D |
(484) |
6,634 |
|
-81% |
|
Dolan Matthew Vincent |
SVP Corporate Development |
|
2022-03-16 |
4 |
AS |
$425.00 |
$291,550 |
D/D |
(686) |
7,118 |
|
-81% |
|
Sayer Kevin R |
Chairman, CEO & President |
|
2022-03-15 |
4 |
AS |
$405.84 |
$1,229,295 |
D/D |
(3,000) |
97,883 |
|
-80% |
|
Dolan Matthew Vincent |
SVP Corporate Development |
|
2022-03-15 |
4 |
AS |
$412.41 |
$419,009 |
D/D |
(1,016) |
7,804 |
|
-80% |
|
Patterson Chad |
EVP, Global Marketing |
|
2022-03-10 |
4 |
AS |
$401.27 |
$311,386 |
D/D |
(776) |
15,228 |
|
-80% |
|
Selvaraj Shelly Ramasamy |
SVP Chief Information Officer |
|
2022-03-10 |
4 |
AS |
$401.27 |
$949,405 |
D/D |
(2,366) |
11,454 |
|
-80% |
|
Leach Jacob Steven |
EVP Chief Technology Officer |
|
2022-03-09 |
4 |
D |
$406.06 |
$1,735,080 |
D/D |
(4,273) |
74,746 |
|
- |
|
Flynn Paul R |
EVP Global Revenue |
|
2022-03-09 |
4 |
D |
$406.06 |
$1,204,770 |
D/D |
(2,967) |
16,183 |
|
- |
|
Shrishrimal Sumi |
SVP Chief Risk Officer |
|
2022-03-09 |
4 |
D |
$406.06 |
$551,019 |
D/D |
(1,357) |
13,789 |
|
- |
|
2278 Records found
|
|
Page 8 of 92 |
|
|